Immuno-oncological treatment of Non-Small-Cell Lung Cancer (NSCLC) in advanced stage with Nivolumab

Abstract

In recent years, significant scientific progress has been made in the therapy of non-small cell lung cancer (NSCLC), which has made possible a better knowledge of this pathology and above all the realization of new personalized therapies. The main therapeutic revolution in advanced NSCLC is immuno-oncology, a new therapeutic strategy that aims to awaken the immune system to fight cancer cells.